T-Therapeutics is on a mission to unlock the power of T cells to treat chronic and infectious diseases.
Founded in 2022, the company is based on technology from Professor Allan Bradley’s laboratory in Cambridge University’s Department of Medicine.
Professor Allan Bradley has previously founded several companies including Kymab, a company developing fully human monoclonal antibodies with a focus on immune-mediated diseases and immuno-oncology therapeutics, which was acquired by Sanofi in 2021 for $1.45 billion.
T-Therapeutics has already raised investment from “a blue-chip syndicate of investors” to support its drug discovery efforts and prepare candidates for clinical development. It is currently building facilities, recruiting staff, and establishing its research operations.
Subscribe for alerts on new companies featured on Startups.Bio
Function Oncology is a precision medicine company advancing a CRISPR-powered personalized functional genomics platform to understand cancer in unprecedented and patient-specific detail. By moving beyond measuring gene sequence to measuring …
Founded in 2023, Mallia Therapeutics is a biopharmaceutical company developing soluble CD83 (sCD83) for the treatment of hair loss. sCD83, which was discovered as an immune modulator by Mallia co-founder …
Empyrean Neuroscience has developed a platform for genetically engineering small molecule therapeutics from fungi and plants to treat neuropsychiatric and neurologic disorders. Through precision targeting and engineering of the fungal …
EnPlusOne Biosciences aims to bring a versatile, sustainable, and scalable RNA synthesis technology to market to unlock development of new RNA drugs, vaccines, and gene-editing therapies. The company's advanced-stage technology …
